Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

379 ARTÍCULOS , VIENDO DEL 121 AL 135

Research and development of anti-Alzheimer's drugs: an analysis based on technology flows measured by patent citations

Xu J, Kong X, Qiu L, Geng X, Hu Y, Wang Y.

Expert Opin Ther Pat. 2014 Jul;24(7):791-800. doi: 10.1517/13543776.2014.915943. Epub 2014 May 5.

Serotonergic therapies for cognitive symptoms in Alzheimer's disease: rationale and current status

Ramirez MJ, Lai MK, Tordera RM, Francis PT.

Drugs. 2014 May;74(7):729-36. doi: 10.1007/s40265-014-0217-5.

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease

Bayer TA, Wirths O.

Acta Neuropathol. 2014;127(6):787-801. doi: 10.1007/s00401-014-1287-x. Epub 2014 May 7.

[Acetylcholinesterase inhibitors for treatment of Alzheimer's disease]

Shinagawa S, Shigeta M.

Brain Nerve. 2014 May;66(5):507-16.

Apolipoprotein E in Alzheimer's disease: an update

Yu JT, Tan L, Hardy J.

Annu Rev Neurosci. 2014;37:79-100. doi: 10.1146/annurev-neuro-071013-014300. Epub 2014 Apr 21.

An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice

Sheline YI, West T, Yarasheski K, Swarm R, Jasielec MS, Fisher JR, Ficker WD, Yan P, Xiong C, Frederiksen C, Grzelak MV, Chott R, Bateman RJ, Morris JC, Mintun MA, Lee JM, Cirrito JR.

Sci Transl Med. 2014 May 14;6(236):236re4. doi: 10.1126/scitranslmed.3008169.

Systematic review of clinical trials assessing pharmacological properties of Salvia species on memory, cognitive impairment and Alzheimer's disease

Miroddi M, Navarra M, Quattropani MC, Calapai F, Gangemi S, Calapai G.

CNS Neurosci Ther. 2014 Jun;20(6):485-95. doi: 10.1111/cns.12270. Epub 2014 Apr 10.

Serotonin 5-HT6 receptor antagonists for the treatment of cognitive deficiency in Alzheimer's disease

Benhamú B, Martín-Fontecha M, Vázquez-Villa H, Pardo L, López-Rodríguez ML.

J Med Chem. 2014 Sep 11;57(17):7160-81. doi: 10.1021/jm5003952. Epub 2014 Jun 3.

Understanding the cause of sporadic Alzheimer's disease

Zetterberg H, Mattsson N.

Expert Rev Neurother. 2014 Jun;14(6):621-30. doi: 10.1586/14737175.2014.915740.

A critique of the drug discovery and phase 3 clinical programs targeting the amyloid hypothesis for Alzheimer disease

Karran E, Hardy J.

Ann Neurol. 2014 Aug;76(2):185-205. doi: 10.1002/ana.24188. Epub 2014 Jul 2.

Dopaminergic modulation of cortical plasticity in Alzheimer's disease patients

Koch G, Di Lorenzo F, Bonnì S, Giacobbe V, Bozzali M, Caltagirone C, Martorana A.

Neuropsychopharmacology. 2014 Oct;39(11):2654-61. doi: 10.1038/npp.2014.119. Epub 2014 May 26.

Which rivastigmine formula is better for heart in elderly patients with Alzheimer's disease: oral or patch?

Isik AT, Soysal P, Yay A.

Am J Alzheimers Dis Other Demen. 2014 Dec;29(8):735-8. doi: 10.1177/1533317514536598. Epub 2014 May 26.

Therapeutic benefits of H₂S in Alzheimer's disease

Wei HJ, Li X, Tang XQ.

J Clin Neurosci. 2014 Oct;21(10):1665-9. doi: 10.1016/j.jocn.2014.01.006. Epub 2014 Jun 2.

The normal and pathologic roles of the Alzheimer's β-secretase, BACE1

Kandalepas PC, Vassar R.

Curr Alzheimer Res. 2014;11(5):441-9. doi: 10.2174/1567205011666140604122059.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias